115974-97-5

Basic information

• Product Name: Benzoic acid, 4-[(1E)-3-methoxy-3-oxo-1-propenyl]-
• CAS NO: 115974-97-5
• Molecular Formula: C11H10O4
• Molecular Weight: 206.198
• Mol File: 115974-97-5.mol
• Article Data: 21

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-[(1E)-3-methoxy-3-oxo-1-propenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[(1E)-3-methoxy-3-oxo-1-propenyl]-(115974-97-5)
• EPA Substance Registry System: Benzoic acid, 4-[(1E)-3-methoxy-3-oxo-1-propenyl]-(115974-97-5)

Safety Data

• Hazardous Substances Data: 115974-97-5(Hazardous Substances Data)

Upstream product

• 16695-14-0 Malonic acid monomethyl ester 
• 619-66-9 4-Carboxybenzaldehyde 
• 456-25-7 p-carboxyphenyl diazonium tetrafluoroborate 
• 292638-85-8 acrylic acid methyl ester 
• 110-89-4 piperidine 
• 38330-80-2 monomethyl monopotassium malonate 
• 623-27-8 terephthalaldehyde, 
• 619-58-9 4-iodobenzoic acid 
• 21204-67-1 methyl (triphenylphosphoranylidene)acetate 
• 619-67-0 4-Hydrazinobenzoic acid 
• 7560-50-1 methyl (2E)-3-(4-formylphenyl)acrylate 
• 5927-18-4 trimethyl phosphonoacetate 

Downstream Products

• 141286-90-0 methyl (E)-3-(4-(hydroxymethyl)phenyl)acrylate 
• 683273-35-0 methyl (2E)-3-{4-[(4-pyridinylamino)carbonyl]phenyl}-2-propenoate 
• 1057107-39-7 C₁₂H₁₂O₄ 
• 215258-27-8 (E)-methyl 3-(4-(dimethylcarbamoyl)phenyl)acrylate 
• 179625-31-1 methyl 4-(methylcarbamoyl)cinnamate 
• 117076-42-3 4-<2-(Methoxycarbonyl)ethenyl>benzoyl-chlorid 
• 52148-89-7 methyl (E)-4-(3-methoxy-3-oxoprop-1-en-1-yl)benzoate 

Relevant articles and documents

Reduction of Electron-Deficient Alkenes Enabled by a Photoinduced Hydrogen Atom Transfer

Direct hydrogen atom transfer from a photoredox-generated Hantzsch ester radical cation to electron-deficient alkenes has enabled the development of an efficient formal hydrogenation under mild, operationally simple conditions. The HAT-driven mechanism is supported by experimental and computational studies. The reaction is applied to a variety of cinnamate derivatives and related structures, irrespective of the presence of electron-donating or electron-withdrawing substituents in the aromatic ring and with good functional group compatibility. (Figure presented.).

HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN

Disclosed herein are hydroxamic acid compounds. Also disclosed is a method of using the hydroxamic acid compounds for treating a condition associated with histone deacetylase 6.

Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors

Inhibition of histone deacetylase (HDAC) has been regarded as a potential therapeutic approach for treatment of multiple diseases including cancer. Based on pharmacophore model of HDAC inhibitors, a series of quinoline-based N-hydroxycinnamamides and N-hydroxybenzamides were designed and synthesized as potent HDAC inhibitors. All target compounds were evaluated for their in?vitro HDAC inhibitory activities and anti-proliferative activities and the best compound 4a surpass Vorinostat in both enzymatic inhibitory activity and cellular anti-proliferative activity. In terms of HDAC isoforms selectivity, compounds 4a exhibited preferable inhibition for class I HDACs, especially for HDAC8, the IC50 value (442?nM) was much lower than that of Vorinostat (7468?nM). Subsequently, we performed class I & IIa HDACs whole cell enzyme assay to evaluate inhibitory activity in whole cell context. Compounds 4a and 4e displayed much better cellular activity for class I HDACs than that for class IIa HDACs, which indicated that 4a and 4e might be potent class I HDAC inhibitors. Meanwhile, flow cytometry analysis showed that compound 4a and 4e can promote cell apoptosis in?vitro.